Drug intelligence / Profile preview

TAK-683

Development stage
Discontinued
Lead developer
Millennium Pharmaceuticals
Modality
Peptides, Small Molecules
Administration
Subcutaneous, Intravenous
01

Overview

TAK-683 is a synthetic nonapeptide analog of the C-terminal decapeptide of kisspeptin (metastin), developed as a potent and metabolically stable agonist of the KISS1 receptor (also known as GPR54 or metastin receptor). TAK-683 acts as a full agonist at KISS1R and has been investigated for its potential to suppress reproductive hormone secretion, including testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH), primarily for the treatment of hormone-dependent diseases such as prostate cancer. Preclinical and clinical studies have demonstrated that TAK-683 initially stimulates LH, FSH, and testosterone release, followed by profound suppression of these hormones and testosterone to castrate levels with continuous administration, suggesting utility in androgen deprivation therapy. It has also been studied for its effects on reproductive physiology in animal models.

Other names
TAK-683 acetateTAK683 acetateTAK 683 acetate
02

Targets

KISS1R (Kisspeptin receptor)

Beyond the preview

Go deeper on TAK-683.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAK-683.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call